Dr Ian Street has over 19 years experience working in the field of drug discovery, within the international pharmaceutical industry, the Australian biotechnology companies AMRAD and Bionomics, and more recently in academia at the Walter and Eliza Hall Institute (WEHI), where in 2001 he established and ran the very successful Centre for High Throughput Chemical Screening, one of the world’s first academic high throughput screening groups. Before working at WEHI, Dr Street spent 11 years in the pharmaceutical and biotech industries. During his career he has worked with some of the world’s leading pharmaceutical companies including, Merck, Aventis, Chiron, GSK, Genentech and Abbott; a body of work which has contributed to compounds entering development, clinical trials and the market. Dr Street now brings these valuable industry links, R&D expertise, and business acumen to academic drug discovery projects in his current roles as Head of the WEHI HTCS Facility and Chief Scientific Officer of the recently established Cancer Therapeutics CRC (CTx). Dr Street now directs CTx’s R&D program and project portfolio. He also manages the CRC’s technology relationship with partners and stakeholders and is responsible for the Portfolio Management Group, CTx’s prime forum for evaluating and selecting new projects and monitoring the performance of projects in the pipeline.
Key Achievements and Awards
- Two compounds that have entered clinical trials in the past 3 years
- The Cancer Therapeutics CRC achieving its first major milestone by nominating a licensing candidate
- Four Patent Applications (3 licensed for commercialization and development)